Silvant Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Silvant Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,483	Closed	-$350K	–	338
2021 Q3	$350K	Hold	3,483	–	–	0.06%	141
2021 Q2	$493K	Hold	3,483	–	–	0.08%	129
2021 Q1	$347K	Hold	3,483	–	–	0.06%	150
2020 Q4	$431K	Hold	3,483	–	–	0.07%	136
2020 Q3	$339K	Hold	3,483	–	–	0.06%	137
2020 Q2	$543K	Hold	3,483	–	–	0.1%	108
2020 Q1	$503K	Hold	3,483	–	–	0.11%	102
2019 Q4	$712K	Hold	3,483	–	–	0.13%	100
2019 Q3	$280K	Buy	3,483 +980	+39%	+$83.2K	0.06%	147
2019 Q2	$236K	Hold	2,503	–	–	0.04%	173
2019 Q1	$214K	Hold	2,503	–	–	0.04%	184
2018 Q4	$140K	Buy	+2,503	New	+$153K	0.03%	200

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Silvant Capital Management's RETA Position: Q4 2021 in Review

Silvant Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 3,483 shares — an estimated $350K sold.

Silvant Capital Management first reported a position in RETA in Q4 2018 and held it in 12 quarters. The position peaked at $712K in Q4 2019. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

Silvant Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
Silvant Capital Management sold 3,483 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $350K.
Silvant Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2018 and held it in 12 quarters.
Silvant Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $712K in Q4 2019.
151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on Silvant Capital Management's 13F filing for Q4 2021, filed 7 Feb 2022.